Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTOR: Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02136134Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Aug 2014; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02136134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02136134.